With our in-house technology platform, scientific expertise in the inner ear, and network of experts, Sensorion can continually develop and optimize its pipeline and market expertise. Consequently, we are poised to expand our pipeline and facilitate other pharmaceutical collaborations.

We select and develop drug candidates from a pool of compounds in late pre-clinical and clinical stage development obtained from partnerships, collaborations and publically available drug libraries.

Sensorion has two therapeutic solutions being evaluated in clinical trials:
SENS-111 and SENS-401

2018 08 Pipeline

Latest news

  • 27 Mar 2019

    Sensorion reports its 2018 annual results. 75% of patients enrolled in the Sens-111 clinical trial. Read

  • 11 Mar 2019

    Sensorion strengthens its financial structure by issuing a €4.7 million nominal bond issue subscribed by new European investors and management. Bpifrance has selected Sensorion for its program "Hub Health Tech". Read

Patient center

Corporate presentation